Conmed (CNMD) Tops Q4 EPS by 1c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
CONMED (CNMD) PT Lowered to $79 at Needham & Company
January 23, 2019 7:34 AM ESTNeedham & Company analyst Mike Matson lowered the price target on CONMED (NASDAQ: CNMD) to $79.00 (from $86.00) while maintaining a Buy rating.
The analyst commented, "CNMD's 4Q18 revenue beat consensus while its EPS was in line with consensus. Management provided 2019 revenue and EPS guidance that... More
